Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions
25 juin 2018 08h00 HE
|
Novelion Therapeutics, Inc.
Data Show Leptin Replacement Therapy Sustainably Decreased Weight Over Time in Patients with Low Baseline Leptin Levels Company plans to initiate Phase 2 proof of concept study in hypoleptinemic...
MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy
01 juin 2018 07h54 HE
|
Novelion Therapeutics, Inc.
Europe represents potentially the largest market for metreleptin with expected authorization in both generalized and partial lipodystrophy VANCOUVER, British Columbia, June 01, 2018 (GLOBE...
Novelion Therapeutics Reports First Quarter 2018 Financial Results
10 mai 2018 08h30 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, B.C., May 10, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living...
Novelion Therapeutics Supports World Lipodystrophy Day
31 mars 2018 06h00 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, March 31, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
Novelion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
15 mars 2018 17h17 HE
|
Novelion Therapeutics, Inc.
Novelion reports 2017 total net revenues of $138.4 million, in line with previously stated guidancePlans underway to address capital structure and advance metreleptin development program VANCOUVER,...
Novelion Therapeutics Subsidiary Enters into $20 Million Term Loan Agreement with Sarissa Capital and Broadfin Capital
15 mars 2018 17h10 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, March 15, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
Novelion Therapeutics Observes Rare Disease Day
28 févr. 2018 07h00 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
Novelion Therapeutics Announces Sentencing of Subsidiary Aegerion Pharmaceuticals
30 janv. 2018 17h51 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
Novelion Therapeutics Announces Cost Reduction Plans and Capital Structure Review
24 janv. 2018 16h01 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
Novelion Therapeutics Appoints Michael Price as Senior Vice President and Chief Financial Officer
04 déc. 2017 08h30 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...